Boundless Bio Stock (NASDAQ:BOLD)


OwnershipFinancialsChart

Previous Close

$2.59

52W Range

$2.33 - $15.24

50D Avg

$2.92

200D Avg

$5.48

Market Cap

$57.09M

Avg Vol (3M)

$93.37K

Beta

-

Div Yield

-

BOLD Company Profile


Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

-

Employees

72

IPO Date

Jul 20, 2016

Website

-

BOLD Performance


BOLD Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-54.80M$-46.47M$-25.30M
Net Income$-49.43M$-45.90M$-25.21M
EBITDA$-53.84M$-45.53M$-24.62M
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in USD